Relative Bioavailability of Lisdexamfetamine 70‐mg Capsules in Fasted and Fed Healthy Adult Volunteers and in Solution: A Single‐Dose, Crossover Pharmacokinetic Study
Authors:
- 7 March 2008
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 48 (3) , 293-302
Abstract
The relative bioavailability of oral lisdexamfetamine dimesylate, a prodrug of d‐amphetamine, and active d‐amphetamine was assessed in an open‐label, single‐dose, 3‐treatment, 3‐period, randomized, crossover study in 18 healthy adult volunteers. Following a fast of at least 10 hours, subjects were administered an intact capsule of 70 mg lisdexamfetamine, a solution containing the capsule contents, or an intact capsule with a high‐fat meal. Standard meals started 4 hours following lisdexamfetamine administration. Blood samples were taken predose (0 hours) and 0.5 to 72 hours postdose, and the concentrations of d‐amphetamine and lisdexamfetamine were measured. AUC and Cmax for d‐amphetamine were similar when lisdexamfetamine 70 mg was administered to healthy adults in the fed or fasted state. The AUC of intact lisdexamfetamine was similar when the latter was taken without food or in solution, but Cmax was lower when lisdexamfetamine was administered with food. The tmax of d‐amphetamine and intact lisdexamfetamine was similar when taken in solution or in the fasted state but was about 1 hour longer when taken with food. Adverse events were typical for amphetamine products. These findings indicate that food does not have a significant effect on d‐amphetamine or lisdexamfetamine bioavailability in healthy adults and that lisdexamfetamine was well tolerated.Keywords
This publication has 8 references indexed in Scilit:
- Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended-Release in Children with ADHD: A Double-Blind, Placebo-Controlled, Crossover Analog Classroom StudyBiological Psychiatry, 2007
- Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group studyClinical Therapeutics, 2007
- Update on attention-deficit/hyperactivity disorderCurrent Opinion in Pediatrics, 2004
- Advances in the Pharmacotherapy of Attention‐Deficit‐Hyperactivity Disorder: Focus on Methylphenidate FormulationsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Physician Perceptions of the Use of Medications for Attention Deficit Hyperactivity DisorderJournal of Managed Care Pharmacy, 2003
- SLI381 (Adderall XR), a Two‐Component, Extended‐Release Formulation of Mixed Amphetamine Salts: Bioavailability of Three Test Formulations and Comparison of Fasted, Fed, and Sprinkled AdministrationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002
- Pharmacotherapy of Attention Deficit Hyperactivity DisorderChild and Adolescent Psychiatric Clinics of North America, 2000
- Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and AdolescentsJAMA, 1998